Overview
- ANSM, France’s medicines agency, fined Novo Nordisk France more than €1.78 million and Eli Lilly France €108,766 on Monday.
- The regulator said the companies’ public campaigns risked indirect promotion of prescription‑only medicines, which cannot be advertised to the general public in France.
- The fines target Novo Nordisk’s Saxenda (€1,000,000) and Wegovy (€783,838) and Eli Lilly’s Mounjaro, all GLP‑1 analogue drugs prescribed for weight management in defined cases.
- ANSM cited wide exposure across billboards, transport, press, and social media and warned that such messages could mislead people as reports of cosmetic misuse of GLP‑1 drugs grow.
- Novo Nordisk said it firmly contests the decision and is weighing appeals, while Eli Lilly said it takes note of the ruling and maintains its campaign complied with health‑communication rules.